The specific treatment of dyslipidemia in patients with diabetes type 2
https://doi.org/10.21518/2079-701X-2016-3-48-53
Abstract
The review tells about the specific diagnosis and treatment of dyslipidemia in patients with diabetes type 2 aimed at preventing serious cardiovascular complications.
About the Authors
S. A. Urazgildeeva
St. Petersburg State University; Clinical Hospital №122 named after L.G. Sokolov
Russian Federation
Russian Federation
O. F. Malygina
North-Western State Medical University named after I.M. Mechnkiov
Russian Federation
Russian Federation
References
1. IDF Diabetes Atlas, 7th Edition, 2015. http//www. diabetesatlas.org/resources/2015-atlas.html,
2. Клинические рекомендации: «Алгоритмы специализированной медицинской помощи больным сахарным диабетом», 7-й выпуск, 2015, под редакцией И.И. Дедова, М.В. Шестаковой.
3. Yusuf S, Hawken S, Ounpuu S et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 coutries (the INTERHEART Study): case-control study. Lancet, 2004, 364(9438): 937-952.
4. Donahoe SM, Atewart GC, McCabe CY et al. Diabetes and mortality following acute coronary syndroms. LAMA, 2007, 298(7): 765-775.
5. Красильникова Е.И., Благосклонная Я.В., Шляхто Е.В. Роль инсулина в развитии атеросклероза. В кн. Атеросклероз. Проблемы патогенеза и терапии. СПб. 2006: 137-163.
6. Глинкина И.В. Лечение нарушений липидного обмена при сахарном диабете 2 типа. Лечащий врач, 2002, 6: 6-8.
7. Sniderman AD, Lamarche B, Tilley J et al. Hypertriglyceridemic hyperapoB in type 2 diabetes. Diabetes Care, 2002, 25(3): 579-582.
8. ESC/EAS Guidelines for the management of dyslipidemias. The Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis, 2011, 217: S1-S44.
9. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (V пересмотр). Атеросклероз и дислипидемии, 2012, 4.
10. Рекомендации по диабету, предиабету и сердечно-сосудистым заболеваниям. Рабочая группа по диабету, предиабету и сердечнососудистым заболеваниям Европейского общества кардиологов (ESC) в сотрудничестве с Европейской ассоциацией по изучению диабета (EASD). Российский кардиологический журнал, 2014, 3(107): 7-61.
11. Kwiterovich PO. Dyslipidemia in Special Groups. Dyslipidemia, 2010: 124.
12. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, 129, 25(Suppl. 2): 1-45.
13. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuv-astatin versus atorvastatin, simvastin and pravastatin across doses (STELLAR trial). Amer. J. Cardiol., 2003, 92(2): 152-160.
14. Уразгильдеева С.А. Гиполипидемическая терапия в практике терапевта в амбулаторных условиях. Медицинский совет в поликлинике, 2013, 6: 56-64.
15. Warraich HL, Wong ND, Rana JS. Role for combination therapy in diabetic dyslipidemia. Curr. Cardiol. Rep., 2015, 17(5): 32.
16. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005, 366(9500): 1849-1861.
17. Home P, Mant, Diaz J, Turner C. Guideline Development Group. Management of type 2 diabetes: summary of updated NICE guidance. BMJ, 2008, 336(7656): 1306-1308.
18. Type 2 diabetes in adults: management. NICE guideline Published: 2 December 2015. nice. org.uk/guidance/ng28.
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylure-as or insulin compared with conventional treatment and risk of complications in patients with 2 diabetes (UKPDS). Lancet, 1998, 352(9178): 837-853.
20. Khaw KT, Wareham N et al. Association of hemoglobin A1C with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann. Intern. Med., 2004, 141(6): 413-420.
21. Hardy DS, Hoelscher DM, Aragaki C et al., Association of glycemic index and glycemic load with risk of incidentcoronary heart disease among Whites and African Americans with and without type 2 diabetes: the Atherosclerosis Risk in Communities Study. Ann. Epidemiol., 2010, 20(8): 610-616.
22. Clinical guidelines: "Algorithms of specialized medical care to patients with diabetes mellitus", 7th Edition, 2015, edited by I.I. Dedov, M.V. Shestakova.
23. Krasil'nikova E.I., Blagosklonnaya Y.V., Shlyakhto E.V. The role of insulin in the development of atherosclerosis. In: Atherosclerosis. Problems of pathogenesis and treatment. SPb. 2006: 137-163.
24. Glinkina I.V. Treatment of lipidosis in diabetes mellitus type 2. Lechaschiy Vrach, 2002, 6: 6-8.
25. Diagnosis and management of lipidosis for the prevention and treatment of atherosclerosis. Russian guidelines (V revision). Ateroscleroz i Dislipidemii, 2012, 4.
26. Guidelines on diabetes, pre-diabetes and cardiovascular disease. The working group on diabetes, pre-diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) in collaboration with the European Association for the Study of Diabetes (EASD). Rossiyskiy Kardiologicheskiy Zhurnal, 2014, 3(107): 7-61.
27. Urazgildeeva S.A. Lipid-lowering therapy in the physician's outpatient practice. Meditsinskiy Sovet v Poliklinike, 2013, 6: 56-64.
Review
For citations:
Urazgildeeva SA, Malygina OF. The specific treatment of dyslipidemia in patients with diabetes type 2. Meditsinskiy sovet = Medical Council. 2016;(3):48-53. (In Russ.) https://doi.org/10.21518/2079-701X-2016-3-48-53
Views:
627
Email this article 